Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05524584 | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | recruiting | Phase 2 | 20 | University of California, IrvineOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04454528 | BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy(BreastVAX) | active not recruiting | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 10, 2026 |
| clinicaltrials |
| NCT05810870 | PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin(SABINA) | active not recruiting | Phase 2 | 14 | MedSIROTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05573555 | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | active not recruiting | Phase 1 / Phase 2 | 20 | PfizerINDUSTRY | 4 | Mar 9, 2026 | clinicaltrials |
| NCT07457359 | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer(NEOTRIO-2) | recruiting | Phase 2 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07458204 | Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer(EPPIL) | not yet recruiting | Phase 2 | 760 | Institut Jean-GodinotOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03384914 | Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 119 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | active not recruiting | Phase 2 | 68 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT01530373 | Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients | recruiting | Phase 2 | 110 | University of ArkansasOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07428018 | Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib(VIOLET) | not yet recruiting | Phase 2 | 150 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03386617 | AKY15-HK-301_NEPA Study | active not recruiting | Phase 2 | 55 | Chinese University of Hong KongOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06268665 | Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy | recruiting | Phase 2 | 86 | University of California, DavisOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06318897 | Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06806930 | Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT) | recruiting | Phase 2 | 90 | George Washington UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07446452 | Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 37 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05325632 | Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | recruiting | Phase 2 | 53 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT07342283 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer | recruiting | Phase 2 | 30 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT07441486 | A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 2, 2026 | clinicaltrials |
| NCT03272334 | Her2-BATS and Pembrolizumab in Metastatic Breast Cancer(Breast-47) | active not recruiting | Phase 1 / Phase 2 | 22 | University of VirginiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03808337 | Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | recruiting | Phase 2 | 145 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07421141 | De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer(Opti-HER2) | active not recruiting | Phase 2 | 186 | National Medical Research Radiological Centre of the Ministry of Health of RussiaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06099769 | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | recruiting | Phase 2 | 201 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06802757 | Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer(PRISM-TNBC) | recruiting | Phase 2 | 72 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02778685 | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | active not recruiting | Phase 2 | 47 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06016387 | Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study | recruiting | Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07193394 | Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer(H3RAKLES) | recruiting | Phase 2 | 20 | Institut CurieOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07423611 | ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer(RACE) | not yet recruiting | Phase 2 | 388 | Fudan UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07419867 | A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI | not yet recruiting | Phase 2 | 300 | Fudan UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT04176848 | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | active not recruiting | Phase 2 | 15 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410559 | Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer | not yet recruiting | Phase 2 | 189 | Fudan UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416253 | Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer | not yet recruiting | Phase 2 | 68 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 18, 2026 | clinicaltrials |
| NCT07417241 | SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study | not yet recruiting | Phase 2 | 100 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 18, 2026 | clinicaltrials |
| NCT04683679 | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer | recruiting | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05074290 | Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 74 | University of FloridaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06291064 | Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer(TARMAC) | recruiting | Phase 2 | 85 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06348134 | Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery | recruiting | Phase 2 | 74 | University of ChicagoOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07145255 | Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | MBrace TherapeuticsINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05892068 | A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain | active not recruiting | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410234 | Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy | not yet recruiting | Phase 2 | 110 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT02624973 | PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial(PETREMAC) | active not recruiting | Phase 2 | 200 | Haukeland University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06517212 | Tirzepatide Weight Loss for MRD+ Early Breast Cancer(TRIM-EBC) | recruiting | Phase 2 | 48 | Baylor Research InstituteOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07071038 | Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients(SWIVEL) | recruiting | Phase 2 | 62 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07208149 | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) | recruiting | Phase 1 / Phase 2 | 42 | Shenzhen Majory Biotechnology Co., Ltd.INDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 220 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Feb 12, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 11, 2026source: clinicaltrials